bioAffinity Technologies Adds to Growing Number of Case Studies Demonstrating Clinical Value of CyPath® Lung [Yahoo! Finance]
bioAffinity Technologies, Inc. (BIAF)
Company Research
Source: Yahoo! Finance
SAN ANTONIO, September 26, 2025 BUSINESS WIRE bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW) , a biotechnology company advancing noninvasive diagnostics for lung cancer and other lung diseases, today released three additional case studies – one in which use of CyPath® Lung led to detecting lung cancer at Stage 1A, its earliest and possibly curative stage, and two where risky invasive procedures were avoided for patients facing difficult healthcare choices. "These three new cases, provided by a Texas pulmonologist who has been using CyPath® Lung for more than a year, reflect what we're hearing from many physicians – CyPath® Lung enhances clinical decision-making by personalizing care and playing a critical role in refining the diagnostic pathway," said Dr. Gordon Downie, Chief Medical Officer of bioAffinity Technologies. "We believe CyPath® Lung can be a transformative tool in the lung cancer diagnostic pathway, especially when imaging results are inconclusive. A positive CyPa
Show less
Read more
Impact Snapshot
Event Time:
BIAF
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BIAF alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BIAF alerts
High impacting bioAffinity Technologies, Inc. news events
Weekly update
A roundup of the hottest topics
BIAF
News
- bioAffinity Technologies’ Noninvasive CyPath® Lung Test to Be Highlighted at American Cancer Society National Lung Cancer RoundtableBusiness Wire
- bioAffinity Technologies Reports Third Quarter 2025 Financial ResultsBusiness Wire
- bioAffinity Technologies Reports Accelerating Month-Over-Month Growth in CyPath® Lung Test VolumeBusiness Wire
- bioAffinity Technologies Announces Acceptance of Australian Patent Application for Platform to Detect and Characterize Multiple Lung DiseasesBusiness Wire
- bioAffinity Technologies Presents Research Supporting CyPath® Lung Processing Methods at CHEST 2025Business Wire
BIAF
Sec Filings
- 12/3/25 - Form 8-K
- 11/14/25 - Form 10-Q
- 11/14/25 - Form 8-K
- BIAF's page on the SEC website